R&D aur Innovation Push
Indian pharma sector growth ke liye ready hai, $120-130 billion by 2030 ka target hai. Lekin, trade tariffs aur supply chain issues jaise global challenges ke liye mazboot domestic R&D framework chahiye. Industry leaders ka kehna hai ki advanced research ko high-value therapies aur complex generics mein transform karne ke liye structured funding zaroori hai, taaki innovation-led model ban sake.
GST Reforms for Manufacturing
Manufacturers, especially medical devices segment mein, GST inversion se pareshan hain. Poly Medicure ka kehna hai ki finished devices par 5% tax, inputs par 18% duty ke muqable mein bahot kam hai, jis se input tax credit jama ho raha hai aur working capital par pressure aa raha hai. Job-work GST rates ko pharma sector ke 5% ke saath align karna aur refund formulas mein input services aur capital goods ko shamil karna critical demands hain.
Child Welfare aur Preventive Health
Child welfare spending par chinta hai, GDP share mein girawat dikhi hai, halanki Union Budget mein allocation thoda badha hai. Paediatrics mein postgraduate training positions badhana aur essential child check-ups ke liye tax deductions increase karna key proposals hain. Aur, non-communicable diseases (NCDs) se 2030 tak 75% mortality hone ka andaaza hai, isiliye preventive healthcare ki taraf focus badhana, diagnostics ko mazboot karna, aur NCD resilience fund banana zaroori mana ja raha hai.
Digital Health aur AI Integration
Healthcare mein Artificial Intelligence (AI) ka integration early diagnosis aur treatment ke liye crucial mana ja raha hai. Philips jaise companies AI-driven innovations ko prioritize karne wale incentives ke liye urge kar rahe hain. Sustainable MedTech manufacturing ecosystem develop karna, PLI schemes se supported, bhi ek priority hai taaki India ek global export hub ban sake.